Apixaban did not increase hemorrhage risk and reduced intracranial hemorrhage compared to aspirin in patients with cryptogenic stroke and atrial cardiopathy.
Does apixaban reduce the risk of hemorrhage compared to aspirin in patients with cryptogenic stroke and evidence of atrial cardiopathy?
In patients with cryptogenic stroke and atrial cardiopathy, apixaban does not increase overall hemorrhage risk and reduces intracranial hemorrhage compared to aspirin.
Absolute Event Rate: 0% vs 0%
We found no increase in any hemorrhage type and a decrease in intracranial hemorrhage with apixaban relative to aspirin in patients with cryptogenic stroke and evidence of atrial cardiopathy. ANN NEUROL 2026.
Kamel et al. (Wed,) reported a other. Apixaban did not increase hemorrhage risk and reduced intracranial hemorrhage compared to aspirin in patients with cryptogenic stroke and atrial cardiopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: